Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
Authors' conclusion
The heterogeneity among the studies in terms of dosing, clinical indications and baseline psychiatric status complicates interpretation, but preliminary evidence suggests modest antidepressant effects and potential therapeutic roles in eating and SUD. Concerns regarding suicidality remain unresolved. In schizophrenia, GLP-1RAs provide clear metabolic benefits but have not demonstrated consistent effects on psychiatric symptomatology.
Study context
- Population
- Studies evaluating the association between GLP-1 RA and psychiatric outcomes (depression, suicidality, eating disorders, substance use disorders (SUD), schizophrenia spectrum disorders)
- Comparison
- GLP-1 RA and psychiatric outcomes
- Outcome
- Psychiatric effects of GLP-1 RA
Methodological detailsDatabases searched: PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Embase, Web of Science
- Databases searched: PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Embase, Web of Science
Pooled result
As reported in the abstract
- Modest antidepressant effects
- Inconsistent associations with suicidality
- Potential therapeutic benefit in disorders of reward regulation
- In schizophrenia, clear metabolic benefits but no consistent effects on psychiatric symptomatology
Original publication
Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence. Diabetes Obes Metab. Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →